Kelun Pharmaceutical (002422) 2018 Annual Report Review: New Product Volume Helps Maintain Faster Growth in Income [Key points of investment]Kelun Ph
Supor (002032) 2019 Interim Report Comments: Performance Meets Expected Repurchase Incentive Plan, Establish Long-Term Mechanism Investment points: I
Meike Home (600337) 2019 First Quarterly Report Review: The rebound in first- and second-tier real estate helps to improve quarterly performance Inve
Feike Electric (603868) 2019 Interim Report Review: Double Pressure on Revenue and Profit Expect Channel Adjustments to Bring Operational Improvements
Oupai Home (603833): Performance Forecast Meets Expected Key Product Categories Investment Highlights Event: The company released a 2019 performan
Lingrui Pharmaceutical (600285) annual report comments: performance is slightly lower than expected marketing integration continues to advance Event:
Xingang shares (600782): Annual report performance is dazzling and profit hits record high Event: The company released its 2018 annual report: in
Shanxi Fenjiu (600809): Significant implementation of strategy Introduction to this report: Performance is in line with expectations. Both ends
Energy war "epidemic": "two barrels of oil" opened full-power masks For stocks, please read Jin Qilin analyst research report, authoritative, profess